Sialivac: An intranasal homologous inactivated split virus vaccine containing bacterial sialidase for the control of avian influenza in poultry

Worrall, E.E.; Sudarisman,; Priadi, Adin

doi:10.1016/j.vaccine.2009.04.058

Cited by 17 publications

(21 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…vaccination in chicken with 100 HAU split H5N1 virus + sialidase and 0.5% (w/v) chitosan already induced mucosal AIV-specific IgA responses at 1 wpv as determined in tracheal swab elutes (Worrall et al, 2009). When the antigen was given with chitosan alone, AIVspecific IgA responses were lower and IgA was not detected at all time points (Worrall et al, 2009). When chickens were vaccinated at 1 day of age with replication-competent Fig.…”

Section: Resultsmentioning

confidence: 98%

“…In the case of AIV, aerosol vaccination using live virus is not desirable because of its zoonotic potential and because of the risk for virus reassortment. Mucosal vaccination via the respiratory route has several advantages: it induces both local and systemic immune responses (Atmar et al, 2007;Tseng et al, 2009;Worrall et al, 2009), it could halt infection already at portal of entry (Yoshikawa et al, 2004) and it is suitable for mass application.…”

Section: Introductionmentioning

confidence: 99%

“…applied whole inactivated AIV (WIV) is poorly immunogenic (Hagenaars et al, 2008), as was also described in chicken for i.n. applied WIV (Worrall et al, 2009) and i.n. applied inactivated NDV (Tseng et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

“…Chitosan has shown promising results in i.n. split virus vaccines in mice (Bacon et al, 2000), split virus and protein vaccines in human (Read et al, 2005;Sui et al, 2010a,b) and a split virus vaccine in poultry (Worrall et al, 2009;Rauw et al, 2010). It was previously shown that CT is an effective mucosal adjuvant in chicken (Vervelde et al, 1998), but CT cannot be used in the field because of its toxicity.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A lack of antibody formation against inactivated influenza virus after aerosol vaccination in presence or absence of adjuvantia

Geus

Haarlem

Poetri

et al. 2011

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

a b s t r a c tIn the poultry industry, infections with avian influenza virus (AIV) can result in significant economic losses. The risk and the size of an outbreak might be restricted by vaccination of poultry. A vaccine that would be used for rapid intervention during an outbreak should be safe to use, highly effective after a single administration and be suitable for mass application. A vaccine that could be applied by spray or aerosol would be suitable for mass application, but respiratory applied inactivated influenza is poorly immunogenic and needs to be adjuvanted. We chose aluminum OH, chitosan, cholera toxin B subunit (CT-B), and Stimune as adjuvant for an aerosolized vaccine with inactivated H9N2. Each adjuvant was tested in two doses. None of the adjuvanted vaccines induced AIV-specific antibodies after single vaccination, measured 1 and 3 weeks after vaccination by aerosol, in contrast to the intramuscularly applied vaccine. The aerosolized vaccine did enter the chickens' respiratory tract as CT-B-specific serum antibodies were detected after 1 week in chickens vaccinated with the CT-B-adjuvanted vaccine. Chickens showed no adverse effects after the aerosol vaccination based on weight gain and clinical signs. The failure to detect AIV-specific antibodies might be due to the concentration of the inactivated virus.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A lack of antibody formation against inactivated influenza virus after aerosol vaccination in presence or absence of adjuvantia

Geus

Haarlem

Poetri

et al. 2011

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

show abstract

“…applied whole inactivated AIV is poorly immunogenic (Hagenaars et al 2008;Worrall et al 2009;de Geus et al 2011) and this is also described in chicken for i.n. applied inactivated NDV (Tseng et al 2009).…”

Section: Mucosal Application Of Inactivated Vaccinesmentioning

confidence: 99%

Induction of respiratory immune responses in the chicken; implications for development of mucosal avian influenza virus vaccines

Geus

Rebel

Vervelde

2012

Veterinary Quarterly

View full text Add to dashboard Cite

The risk and the size of an outbreak of avian influenza virus (AIV) could be restricted by vaccination of poultry. A vaccine used for rapid intervention during an AIV outbreak should be safe, highly effective after a single administration and suitable for mass application. In the case of AIV, aerosol vaccination using live virus is not desirable because of its zoonotic potential and because of the risk for virus reassortment. The rational design of novel mucosal-inactivated vaccines against AIV requires a comprehensive knowledge of the structure and function of the lung-associated immune system in birds in order to target vaccines appropriately and to design efficient mucosal adjuvants. This review addresses our current understanding of the induction of respiratory immune responses in the chicken. Furthermore, possible mucosal vaccination strategies for AIV are highlighted.

show abstract

One‐Step Preparation of Multifunctional Chitosan Microspheres by a Simple Sonochemical Method

Skirtenko

Tzanov

Gedanken

et al. 2009

Chemistry A European J

View full text Add to dashboard Cite

Chitosan is a biodegradable natural polymer with great potential for pharmaceutical applications due to its biocompatibility, high charge density, nontoxicity, and mucoadhesion properties. Processing techniques for the preparation of chitosan microspheres have been extensively developed since the 1980s. The present paper describes for the first time a fast and one-step process for the preparation of stable chitosan microspheres by a simple sonochemical method. The microspheres were characterized by their particle size, surface morphology, stability, and drug-entrapment efficiency. The average size of the microspheres was found to be around 1 mum with a narrow size distribution, which enabled them to be used for in vivo applications. The encapsulation of different dyes into these microspheres was readily achieved with more than 75 % efficacy by dissolving them into the organic phase before sonication. The chitosan microspheres demonstrated excellent stability toward acidic and basic conditions ranging from pH 4 to 9, thereby indicating their implementation as possible therapeutic and diagnostic agents. The stability of these microspheres appears to be contributed from intermolecular imine cross-linking in addition to other noncovalent interactions. The ability of the surface-exposed amino groups of chitosan microspheres to undergo chemical conjugation with potential drugs and/or targeting vectors was determined by their reaction with fluorescein isothiocyanate (FITC) and fluorescamine followed by confocal microscopy.

show abstract

Sialivac: An intranasal homologous inactivated split virus vaccine containing bacterial sialidase for the control of avian influenza in poultry

Cited by 17 publications

References 21 publications

A lack of antibody formation against inactivated influenza virus after aerosol vaccination in presence or absence of adjuvantia

A lack of antibody formation against inactivated influenza virus after aerosol vaccination in presence or absence of adjuvantia

Induction of respiratory immune responses in the chicken; implications for development of mucosal avian influenza virus vaccines

One‐Step Preparation of Multifunctional Chitosan Microspheres by a Simple Sonochemical Method

Contact Info

Product

Resources

About